

2015-09-29

## TCF1 Is Required for the T Follicular Helper Cell Response to Viral Infection

Tuoqi Wu

*National Human Genome Research Institute (NHGRI)*

*Et al.*

Let us know how access to this document benefits you.

Follow this and additional works at: <https://escholarship.umassmed.edu/oapubs>



Part of the [Cellular and Molecular Physiology Commons](#), [Immunopathology Commons](#), and the [Virology Commons](#)

---

### Repository Citation

Wu T, Shin H, Moseman EA, Ji Y, Huang B, Harly C, Sen JM, Berg LJ, Gattinoni L, McGavern DB, Schwartzberg PL. (2015). TCF1 Is Required for the T Follicular Helper Cell Response to Viral Infection. Open Access Articles. <https://doi.org/10.1016/j.celrep.2015.08.049>. Retrieved from <https://escholarship.umassmed.edu/oapubs/2603>


Creative Commons License



This work is licensed under a [Creative Commons Attribution-Noncommercial-No Derivative Works 4.0 License](#). This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in Open Access Articles by an authorized administrator of eScholarship@UMMS. For more information, please contact [Lisa.Palmer@umassmed.edu](mailto:Lisa.Palmer@umassmed.edu).

## TCF1 Is Required for the T Follicular Helper Cell Response to Viral Infection

### Graphical Abstract



### Authors

Tuoqi Wu, Hyun Mu Shin, E. Ashley Moseman, ..., Luca Gattinoni, Dorian B. McGavern, Pamela L. Schwartzberg

### Correspondence

tuoqiwu@gmail.com (T.W.), pams@nhgri.nih.gov (P.L.S.)

### In Brief

T<sub>FH</sub> cells are critical for long-term humoral responses. Wu et al. examine the molecular mechanisms that govern the choice of activated CD4 T cells between T<sub>FH</sub> and Th1 fates, and they find that the transcription factor TCF1 promotes viral-specific T<sub>FH</sub> cell responses through a negative feedback loop with IL-2 and Blimp1.

### Highlights

- TCF1 and Blimp1 are reciprocally expressed in viral-specific T<sub>FH</sub> and Th1 cells
- TCF1 is intrinsically required for viral-specific T<sub>FH</sub> cell responses
- TCF1 forms negative feedback loops with IL-2 and Blimp1
- TCF1 maintains the transcriptional and metabolic signatures of T<sub>FH</sub> cells

### Accession Numbers

GSE65660



# TCF1 Is Required for the T Follicular Helper Cell Response to Viral Infection

Tuoqi Wu,<sup>1,\*</sup> Hyun Mu Shin,<sup>2</sup> E. Ashley Moseman,<sup>3</sup> Yun Ji,<sup>4</sup> Bonnie Huang,<sup>1</sup> Christelle Harly,<sup>4</sup> Jyoti M. Sen,<sup>5</sup> Leslie J. Berg,<sup>2</sup> Luca Gattinoni,<sup>4</sup> Dorian B. McGavern,<sup>3</sup> and Pamela L. Schwartzberg<sup>1,\*</sup>

<sup>1</sup>National Human Genome Research Institute (NHGRI), NIH, Bethesda, MD 20892, USA

<sup>2</sup>Department of Pathology, University of Massachusetts Medical School, Worcester, MA 01655, USA

<sup>3</sup>National Institute of Neurological Disorders and Stroke (NINDS), NIH, Bethesda, MD 20892, USA

<sup>4</sup>National Cancer Institute (NCI), NIH, Bethesda, MD 20892, USA

<sup>5</sup>National Institute on Aging (NIA), NIH, Baltimore, MD 21224, USA

\*Correspondence: [tuoqiwu@gmail.com](mailto:tuoqiwu@gmail.com) (T.W.), [pams@nhgri.nih.gov](mailto:pams@nhgri.nih.gov) (P.L.S.)

<http://dx.doi.org/10.1016/j.celrep.2015.08.049>

This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## SUMMARY

T follicular helper (T<sub>FH</sub>) and T helper 1 (Th1) cells generated after viral infections are critical for the control of infection and the development of immunological memory. However, the mechanisms that govern the differentiation and maintenance of these two distinct lineages during viral infection remain unclear. We found that viral-specific T<sub>FH</sub> and Th1 cells showed reciprocal expression of the transcription factors TCF1 and Blimp1 early after infection, even before the differential expression of the canonical T<sub>FH</sub> marker CXCR5. Furthermore, TCF1 was intrinsically required for the T<sub>FH</sub> cell response to viral infection; in the absence of TCF1, the T<sub>FH</sub> cell response was severely compromised, and the remaining TCF1-deficient T<sub>FH</sub> cells failed to maintain T<sub>FH</sub>-associated transcriptional and metabolic signatures, which were distinct from those in Th1 cells. Mechanistically, TCF1 functioned through forming negative feedback loops with IL-2 and Blimp1. Our findings demonstrate an essential role of TCF1 in T<sub>FH</sub> cell responses to viral infection.


## INTRODUCTION

CD4 T cells constitute an essential force of the adaptive immune system and are critical for vaccination and immune responses against infections and tumors. CD4 T cells modulate the immune response through various mechanisms, including secretion of cytokines and direct cell-cell interaction. Depending on the antigen, microenvironment, and cytokine milieu, activated CD4 T cells can develop into distinct effector populations, each characterized by unique effector functions and differentiation programming (Crotty, 2011; Zhou et al., 2009). One major function of CD4 T cells is to help the humoral immune response, a function that is carried out by a CD4 subset known as T follicular helper (T<sub>FH</sub>) cells (Cannons et al., 2013; Crotty, 2011). T<sub>FH</sub> cells express a set of surface markers, such as CXCR5, which enable

them to migrate to the B cell follicle and distinguish them from other CD4 subsets. T<sub>FH</sub> cells provide crucial help for the initiation and maintenance of germinal centers (GCs), which are indispensable for antibody affinity maturation and the development of long-term humoral immunity conferred by long-lived plasma cells and memory B cells (Victoria and Nussenzweig, 2012). T<sub>FH</sub> cells signal to antigen-presenting cognate B cells through the secretion of cytokines, such as IL-4 and IL-21, as well as the expression of CD40L and ICOS that engage their binding partners on B cells (Crotty, 2011).

T<sub>FH</sub> cells express high levels of Bcl6, a transcriptional repressor, which is essential for T<sub>FH</sub> cell differentiation (Johnston et al., 2009; Nurieva et al., 2009; Yu et al., 2009a). In contrast, Blimp1, an antagonist of Bcl6, is highly expressed by non-T<sub>FH</sub> effector cells and suppresses T<sub>FH</sub> cell differentiation (Johnston et al., 2009). Bcl6 expression is triggered in activated T cells early after antigen exposure through the interaction between dendritic cells (DCs) and T cells (Baumjohann et al., 2011; Choi et al., 2011). After priming by DCs, T<sub>FH</sub> cells upregulate CXCR5, downregulate CCR7, and move to the T-B zone border where they interact with cognate B cells (Allen et al., 2007; Baumjohann et al., 2011; Haynes et al., 2007). T<sub>FH</sub> and pre-GC B cells then migrate into the B cell follicle and initiate the GC reaction (Crotty, 2011). The interaction with cognate B cells is required for the maintenance and expansion of T<sub>FH</sub> cells (Baumjohann et al., 2011; Choi et al., 2011). In contrast, IL-2 signaling restricts the T<sub>FH</sub> cell response via STAT5- and Blimp1-mediated pathways (Ballesteros-Tato et al., 2012; Johnston et al., 2012). However, despite recent progress on the regulation of T<sub>FH</sub> cell differentiation, many molecular mechanisms involved in the initiation and maintenance of T<sub>FH</sub> cells remain to be elucidated.

T cell factor 1 (TCF1) is a key transcription factor of the Wnt signaling pathway, which activates Wnt target genes when bound by  $\beta$ -catenin (Verbeek et al., 1995). Multiple TCF1 isoforms are produced as a result of alternative splicing and dual promoter usage of the *Tcf7* gene and can be grouped into long and short isoforms having or lacking the  $\beta$ -catenin-binding domain (Van de Wetering et al., 1996). TCF1 is induced by Notch signaling during T cell development and is highly expressed in thymocytes and mature naive T cells (Xue and Zhao, 2012). Various stages of T cell development, such as T cell lineage



**Figure 1. TCF1 Is Differentially Expressed between T<sub>HH</sub> and Th1 Cells after LCMV Infection**

(A and B) 10<sup>6</sup> CellTrace Violet-labeled (CTV) purified naive CD45.1<sup>+</sup> Blimp1-YFP SMARTA CD4 T cells were transferred into C57BL/6 mice followed by infection with LCMV Armstrong. Splenocytes (gated on CD45.1<sup>+</sup> SMARTA CD4 T cells) were analyzed on days 1.5, 2, and 3 p.i. (A) Analyses of Blimp1-YFP, CXCR5, and TCF1 expression are shown. (B) Analyses of CTV dilution plus phenotypic markers are shown.

(C) C57BL/6 mice received 10<sup>4</sup> purified naive CD45.1<sup>+</sup> Blimp1-YFP SMARTA CD4 T cells and were infected with LCMV Armstrong. Splenocytes (gated on SMARTA cells) were analyzed on day 7 p.i. for Blimp1-YFP, CXCR5, and TCF1. (Right) TCF1 in SMARTA cells (blue) and host B cells (red) is shown.

(D) TCF1 protein in day 3 T<sub>HH</sub> (CXCR5<sup>high</sup>Tim3<sup>low</sup>), day 3 Th1 (CXCR5<sup>low</sup>Tim3<sup>high</sup>), day 8 T<sub>HH</sub> (CXCR5<sup>high</sup>SLAMF7<sup>low</sup>), and day 8 Th1 (CXCR5<sup>low</sup>SLAMF7<sup>high</sup>) SMARTA CD4 T cells.  $\beta$ -actin was used as a loading control.

Data in (A) and (B) are from a single experiment ( $n \geq 2$  per time point), representative of more than four independent experiments. Data in (C) are from a single experiment ( $n = 3$ ) representative of two independent experiments. Western blots are representative of two independent experiments.

commitment of hematopoietic progenitor cells,  $\beta$  selection, and development from double-negative (DN) to double-positive (DP) thymocytes, are regulated by TCF1 (Germar et al., 2011; Okamura et al., 1998; Weber et al., 2011; Yu et al., 2012). During the CD8 T cell response, TCF1 is required for the development of central memory CD8 T cells and optimal recall response by memory cells (Zhou et al., 2010). In CD4 T cells, TCF1 promotes Th2 differentiation by inducing GATA3 expression and restricts IFN $\gamma$  expression by T helper 1 (Th1) cells (Yu et al., 2009b). However, the role of TCF1 in the T<sub>HH</sub> cell differentiation is still unknown.

In this study, we found that, very early after viral infection, effector CD4 T cells differentiate into TCF1<sup>high</sup>Blimp1<sup>low</sup> T<sub>HH</sub> and TCF1<sup>low</sup>Blimp1<sup>high</sup> Th1 cells. Notably, *Tcf7* deficiency led to a T-cell-intrinsic defect in viral-specific T<sub>HH</sub> cell responses, associated with decreased T<sub>HH</sub> cells and reduced GCs. Mechanistically, we found that TCF1 is required for the generation and maintenance of distinct transcriptional and metabolic signatures of T<sub>HH</sub> cells, including repression of *Ii2ra* and *Prdm1*, the gene products of which limit T<sub>HH</sub> cell responses. Together, our data demonstrate that TCF1 is essential for the anti-viral T<sub>HH</sub> cell response.

## RESULTS

### Viral-Specific Effector CD4 T Cells Can Be Separated into TCF1<sup>high</sup>Blimp1<sup>low</sup> T<sub>HH</sub> and TCF1<sup>low</sup>Blimp1<sup>high</sup> Th1 Cells

During viral and intracellular bacterial infections, effector CD4 T cells can be divided into CXCR5<sup>high</sup>Bcl6<sup>high</sup> T<sub>HH</sub> and CXCR5<sup>low</sup> Blimp1<sup>high</sup> Th1 cells before the initiation of GCs (Choi et al., 2011, 2013; Pepper et al., 2011). However, it remains unclear how early these two lineages start to diverge. To address this, we used SMARTA CD4 T cells, which express a transgenic T cell receptor

(TCR) that recognizes the GP66-77 epitope on lymphocytic choriomeningitis virus (LCMV), crossed to a Blimp1-YFP reporter to track Blimp1 expression during the response to LCMV (Fooksman et al., 2014; Oxenius et al., 1998). Strikingly, bimodal expression of Blimp1 was observed as early as day 1.5 post-infection (p.i.) (Figures 1A, S1A, and S1B), when SMARTA cells had only undergone the first few cell divisions (Figure 1B). Interestingly, at this early time point, CXCR5 was expressed by both Blimp1<sup>high</sup> and Blimp1<sup>low</sup> cells (Figure 1A). However, after day 2 p.i., Blimp1<sup>high</sup> SMARTA cells started to express lower levels of CXCR5 than their Blimp1<sup>low</sup> counterparts (Figures 1A and S1B). Accordingly, analysis of splenic sections from mice transferred with Blimp1-YFP reporter SMARTA cells revealed that both T<sub>HH</sub> (Blimp1<sup>low</sup>) and Th1 (Blimp1<sup>high</sup>) SMARTA cells could be found in splenic B cell follicles on day 2 p.i. (Figure S1D). In contrast, by day 3 p.i., most SMARTA cells in B cell follicles were Blimp1<sup>low</sup> T<sub>HH</sub> cells, consistent with the lower expression of CXCR5 in Th1 cells (Figure S1E).

To further characterize the differentiation program of early T<sub>HH</sub> and Th1 cells, we looked for transcription factors that were differentially expressed between these cells. Based on our unpublished RNA sequencing studies and previously published data (Choi et al., 2013), T<sub>HH</sub> cells express much higher levels of *Tcf7* transcripts than their Th1 counterparts. To evaluate this further, we analyzed the kinetics of expression of TCF1, the protein encoded by *Tcf7*, at a single-cell level early after LCMV infection by flow cytometry (Figures 1A, 1B, S1A, and S1C). SMARTA T cells could be readily separated into TCF1<sup>high</sup> and TCF1<sup>low</sup> populations starting from day 2 p.i., likely as a result of the gradual downregulation of TCF1 (which is expressed in naive cells) in a subset of SMARTA cells (Figures 1A and S1A). Notably, whereas TCF1<sup>high</sup> SMARTA cells maintained high CXCR5, TCF1<sup>low</sup> SMARTA cells expressed less CXCR5 after day 2 p.i. (Figures 1A and S1C). In addition, there was a clear inverse

correlation between TCF1 and Blimp1, as well as a positive correlation between TCF1 and Bcl6 (Figures 1A and S1F), suggesting that TCF1 can be used to distinguish T<sub>FH</sub> cells from Th1 cells. Indeed, TCF1<sup>high</sup> SMARTA cells were almost exclusively found in the CXCR5<sup>high</sup>Blimp1<sup>low</sup> T<sub>FH</sub> subset, while TCF1<sup>low</sup> cells were primarily in the CXCR5<sup>low</sup>Blimp1<sup>high</sup> Th1 subset (Figure S1G).

IL-2 signaling suppresses T<sub>FH</sub> development, and early Th1 cells express more CD25, the high-affinity IL-2 receptor, than early T<sub>FH</sub> cells (Ballesteros-Tato et al., 2012; Choi et al., 2011; Johnston et al., 2012; Pepper et al., 2011). We found that, while most SMARTA cells showed substantial CD25 expression on day 1.5 p.i., TCF1<sup>high</sup> T<sub>FH</sub> cells downregulated CD25 much faster than TCF1<sup>low</sup> Th1 cells (Figure S1F). We also found that expression of Tim3, a co-inhibitory receptor expressed by exhausted CD8 T cells (Jin et al., 2010; Sakuishi et al., 2010), correlated well with Blimp1 (Figure S1F). We, therefore, used Tim3 as an early Th1 marker when the Blimp1-YFP reporter was not available.

To determine whether the dichotomy of Blimp1 and TCF1 expression between T<sub>FH</sub> and Th1 cells was maintained later during infection when T<sub>FH</sub> cell responses rely on antigen presentation by GC B cells (Baumjohann et al., 2011; Choi et al., 2011), we examined their expression in SMARTA cells 1 week after LCMV infection. As expected, CXCR5<sup>high</sup> T<sub>FH</sub> cells mostly expressed low levels of Blimp1 (Figures 1C and S1H) and SLAM (Figure S1I; Johnston et al., 2009). Strikingly, TCF1 still negatively correlated with Blimp1 expression; co-staining of TCF1 and Blimp1 clearly separated SMARTA into two populations (Figures 1C and S1H). Furthermore, TCF1<sup>high</sup> cells were again primarily in the CXCR5<sup>high</sup>Blimp1<sup>low</sup> T<sub>FH</sub> population, while the CXCR5<sup>low</sup>Blimp1<sup>high</sup> cells contained mostly TCF1<sup>low</sup> cells (Figure S1J) in which TCF staining was only slightly higher than that in B cells, which do not express TCF1 (Staal and Clevers, 2000; Figure 1C). *Tcf7* encodes multiple isoforms as a result of alternative splicing and dual promoter usage (Van de Wetering et al., 1996). The flow cytometry antibody we used binds to the N-terminal  $\beta$ -catenin-binding domain and, therefore, only recognizes the long isoforms. To further assess TCF1 expression, we sorted T<sub>FH</sub> and Th1 SMARTA cells on day 3 p.i. and day 8 p.i., and we evaluated TCF1 protein levels by immunoblots using an antibody that recognizes all isoforms. While T<sub>FH</sub> cells from both time points expressed multiple isoforms with or without the  $\beta$ -catenin-binding domain, expression of all TCF1 isoforms was very low in Th1 cells, particularly on day 3 p.i. (Figure 1D). Thus, TCF1 protein levels are high in T<sub>FH</sub> but low in Th1 cells in both pre-GC phase and GC phase of the immune response to LCMV.

### Tcf7 Is Repressed by IL-2 and Blimp1

The bifurcation in *Tcf7* expression between T<sub>FH</sub> and Th1 cells prompted us to investigate which signals induce the loss of *Tcf7* in Th1 cells. IL-2 signaling suppresses T<sub>FH</sub> differentiation and Bcl6 expression in activated CD4 T cells (Ballesteros-Tato et al., 2012; Johnston et al., 2012; Oestreich et al., 2012). The fact that TCF1<sup>low</sup> Th1 cells expressed more CD25, the high-affinity IL-2 receptor, than TCF1<sup>high</sup> T<sub>FH</sub> cells (Figure S1F) suggested IL-2 might suppress *Tcf7*. To examine this possibility, we monitored the effect of IL-2 on in-vitro-activated CD4 T cells. We stim-


ulated CD4 T cells with anti-CD3 $\epsilon$  and CD28 for 3 days, then washed and cultured cells with or without IL-2 for 1 additional day. CD4 T cells receiving IL-2 expressed higher surface CD25, consistent with the role of IL-2 in promoting CD25 expression. Moreover, these cells expressed 50% less TCF1 than cells cultured without IL-2 (Figure 2A). Thus, differential IL-2 signals between T<sub>FH</sub> and Th1 cells may contribute to differences in TCF1 levels.

A previous study suggested that IL-2 suppresses T<sub>FH</sub> differentiation via Blimp1 (Johnston et al., 2012). The inverse correlation between TCF1 and Blimp1 expression suggested that Blimp1 might also selectively repress the *Tcf7* locus in Th1 cells. To examine this possibility, we transduced SMARTA cells with retroviral vectors expressing a scrambled small hairpin RNA (shRNA) or shRNA targeting *Prdm1*, which encodes Blimp1, and we analyzed the effect on TCF1 levels in Th1 cells. Knockdown of Blimp1 caused an increase in TCF1 expression in CXCR5<sup>low</sup>CD25<sup>high</sup> Th1 SMARTA cells on day 3 p.i., compared to untransduced or control-vector-transduced Th1 SMARTA cells (Figure 2B). Interestingly, the region 30 kb upstream of the *Tcf7* transcription start site (TSS) (Figure S2) contains evolutionarily conserved sequences with Blimp1-binding motifs (GAAAG) (Kuo and Calame, 2004). This region is bound by TCF1 itself, as well as other transcription factors based on published chromatin immunoprecipitation sequencing (ChIP-seq) data from different cell types, and has been shown to regulate *Tcf7* transcription (Germar et al., 2011; Steinke et al., 2014). Indeed, using ChIP assays, we found that Blimp1 physically interacted with this region in T<sub>FH</sub> and Th1 SMARTA cells (Figure 2C); however, the binding of Blimp1 was significantly stronger in Th1 cells than in T<sub>FH</sub> cells, consistent with the different abundance of Blimp1 in the two populations. We also observed more H3 K4 trimethylation (H3K4me3), which is associated with active transcription (Jenuwein and Allis, 2001), in this region in T<sub>FH</sub> cells than in Th1 cells, while more H3 K27 trimethylation (H3K27me3), which is linked to transcriptional repression (Cao et al., 2002), was found in Th1 cells than in T<sub>FH</sub> cells (Figure 2D). Furthermore, the  $-30$ -kb region increased luciferase activity 2-fold relative to a control luciferase construct; however, overexpression of Blimp1 repressed the enhancer activity of this region (Figure 2E). Thus, Blimp1 may suppress *Tcf7* expression in Th1 cells.

### Tcf7 Deficiency Causes a Severe Defect in the T<sub>FH</sub> Cell Response to LCMV

The high expression of TCF1 in T<sub>FH</sub> cells suggested a potential role of TCF1 in T<sub>FH</sub> cell development. *Tcf7* is a key player in multiple steps during T cell development (Verbeek et al., 1995; Weber et al., 2011). To study the immune response of mature T cells, we bred mice carrying a conditional *Tcf7* allele to CD4-Cre mice, which initiate Cre activity in DP thymocytes (Steinke et al., 2014), to generate *Tcf7* conditional (cKO) mice. Cre-mediated deletion caused more than a 10-fold reduction in TCF1 in CD4 T cells (Figure S3A). Although naive cKO mice had lower CD4 T cell frequencies than wild-type (WT) controls, frequencies of CD44<sup>high</sup> CD4 T cells were comparable (Figure S3B). We then infected cKO and WT mice with LCMV and analyzed LCMV-specific CD4 T cell responses using the GP66-77 IA<sup>b</sup> tetramer on day





**Figure 2. IL-2 and Blimp1 Negatively Regulate TCF1 Expression**

(A) Naive CD4 T cells were stimulated with anti-CD3 and anti-CD28 for 3 days and then cultured with or without IL-2 for 1 day, and the mean fluorescence intensity (MFI) of CD25 and TCF1 was determined by flow cytometry. Unpaired Student's t tests were performed; error bars represent SD. Data are from a single experiment representative of four independent experiments.

(B)  $10^6$  SMARTA CD4 T cells were transduced with retroviruses containing a scrambled control sequence or shRNA for *Prdm1* and transferred into C57BL/6 recipients followed by infection with LCMV. On day 3 p.i., TCF1 expression in Th1 ( $CXCR5^{low}CD25^{high}$ ) SMARTA cells was determined. Paired Student's t tests were performed between transduced (GFP<sup>+</sup>) and untransduced populations within each group. Each line represents data from one individual mouse. Data are from a single experiment (n = 4 per group) representative of two independent experiments.

(C and D) On day 8 p.i., T<sub>FH</sub> and Th1 SMARTA T cells were isolated, and ChIP assays were performed with antibodies to Blimp-1 (C) or a control IgG and with antibodies to modified histone H3 (D) as indicated. ChIPs were amplified by qRT-PCR for the indicated region. Data are the mean ± SEM of three independent experiments. Significance was determined by an unpaired t test.

(E) 293T cells were co-transfected with pGL3 SV40 promoter vector containing *Tcf7* -30-kb region and MSCV-IRES-GFP (MIG) with or without Blimp1. Luciferase activity was normalized to Renilla activity and adjusted to the fold increase over empty pGL3 SV40 vector. Data are the mean ± SD of three independent transfections in one of two independent experiments. Significance was determined by an unpaired t test.


10 p.i. We used CXCR5, PD1, and Bcl6 to stain T<sub>FH</sub> cells and SLAM to stain Th1 cells. While the ratio of CXCR5<sup>high</sup>SLAM<sup>low</sup> T<sub>FH</sub> to CXCR5<sup>low</sup>SLAM<sup>high</sup> Th1 tetramer<sup>+</sup> CD4 T cells was close to 1 in WT mice, the frequency of T<sub>FH</sub> cells among tetramer<sup>+</sup> cells in cKO mice was markedly decreased (Figure 3A). We also observed a substantial loss of tetramer<sup>+</sup> CXCR5<sup>high</sup>PD1<sup>high</sup> and CXCR5<sup>high</sup>Bcl6<sup>high</sup> GC-T<sub>FH</sub> populations in cKO mice. Accordingly, the number of GP66-77-specific T<sub>FH</sub> cells in the spleens of cKO mice was reduced more than 6-fold (Figure 3B). In contrast, the numbers of GP66-77-specific Th1 cells were not significantly different between cKO and WT mice. TCF1 levels in GP66-77-specific CD4 T cells were substantially decreased, even in the remaining CXCR5<sup>+</sup> T<sub>FH</sub> cells, suggesting that the small fraction of T<sub>FH</sub> cells in cKO mice was not likely caused by incomplete recombination (Figure S3C). Moreover, defective T<sub>FH</sub> cell responses in cKO mice were not unique to one epitope, as the frequencies of T<sub>FH</sub> cells among total CD44<sup>high</sup> CD4 T cells and total T<sub>FH</sub> counts in cKO spleens also were reduced (Figure 3C). Consistent with the role of T<sub>FH</sub> cells in supporting humoral responses and GC formation (Crotty, 2011), the numbers of GC (GL7<sup>high</sup>FAS<sup>high</sup>) B cells and activated (IgD<sup>low</sup>FAS<sup>high</sup>) B cells in the cKO mice were less than half of those in WT mice (Figure 3D).

To rule out that loss of TCF1 during thymocyte development compromised T<sub>FH</sub> differentiation in cKO mice, we crossed the conditional *Tcf7* to ERT2-Cre mice, which activate Cre by tamoxifen treatment (Seibler et al., 2003). By treating the inducible *Tcf7* knockout mice (iKO) with tamoxifen for several days immediately prior to LCMV infection, we ensured that iKO T cells had undergone thymic development similar to their ERT2-Cre<sup>neg</sup> counter-

parts (data not shown). Similar to cKO mice, T<sub>FH</sub> cell responses in tamoxifen-treated iKO mice on day 10 p.i. were severely compromised compared to vehicle-treated counterparts, confirming that *Tcf7* is critical for T<sub>FH</sub> cell responses during LCMV infection (Figure 3E).

### T<sub>FH</sub> Cells Require TCF1 in a CD4 T-Cell-Autonomous Manner

In the above experiments, TCF1 was deleted in both CD4 and CD8 T cells in cKO and iKO mice. To determine whether defective T<sub>FH</sub> cell responses in *Tcf7* KO mice were intrinsic to CD4 T cells, we crossed *Tcf7* cKO mice to SMARTA mice. Congenically marked naive CD4 T cells from WT and cKO SMARTA mice were isolated, mixed at 1:1 ratios, and adoptively transferred to WT CD45.1 mice, which were subsequently infected with LCMV (Figure 4A). By mixing WT and cKO SMARTA cells, we could compare the two within each recipient exposed to the same exact conditions and determine their phenotype with higher accuracy and sensitivity. T<sub>FH</sub> cell differentiation involves an early B-cell-independent phase and a subsequent B-cell-dependent phase (Baumjohann et al., 2011; Choi et al., 2011). To investigate the impact of *Tcf7* deficiency on each phase of T<sub>FH</sub> differentiation, we monitored CD4 T cell responses on days 3 and 8 p.i. On day 3 p.i., loss of TCF1 preferentially reduced T<sub>FH</sub> cell responses as evidenced by the decreased frequencies of CXCR5<sup>high</sup>Tim3<sup>low</sup> as well as CXCR5<sup>high</sup>Bcl6<sup>high</sup> cells among cKO SMARTA cells (Figures 4B, 4C, and S4B). *Tcf7* deficiency also caused a reduction in the number of T<sub>FH</sub> (CXCR5<sup>high</sup>Tim3<sup>low</sup>) SMARTA cells and, to a lesser extent, the number of Th1 (CXCR5<sup>low</sup>Tim3<sup>high</sup>)



**Figure 3. TCF1 Is Required for the Differentiation of T<sub>FH</sub> Cells**

(A–D) *Tcf7*<sup>loxP/loxP</sup>; CD4-Cre (cKO) mice and littermate controls (WT) were infected with LCMV and splenocytes isolated on day 10 p.i. (A) Analyses of CXCR5, SLAM, PD1, and Bcl6 in WT and cKO GP66-77 IA<sup>b</sup> tetramer<sup>+</sup> CD4 T cells are shown. (B) Numbers of GP66-77 IA<sup>b</sup> tetramer<sup>+</sup> CXCR5<sup>high</sup> SLAM<sup>low</sup> (T<sub>FH</sub>) and CXCR5<sup>low</sup>SLAM<sup>high</sup> (Th1) CD4 T cells in spleens of WT or cKO mice are shown. (C) Representative fluorescence-activated cell sorting (FACS) plots of CXCR5 and SLAM staining (gated on CD44<sup>high</sup> CD4 T cells) and numbers of CXCR5<sup>high</sup>SLAM<sup>low</sup>CD44<sup>high</sup> (T<sub>FH</sub>) CD4 T cells in spleens are shown. (D) Representative FACS plots and numbers of FAS<sup>high</sup>GL7<sup>high</sup> (GC) B cells (gated on CD19<sup>+</sup>B220<sup>+</sup> cells) and activated (Igd<sup>low</sup>FAS<sup>high</sup>) B cells in WT and cKO spleens are shown. (E) *Tcf7*<sup>loxP/loxP</sup>; ERT2-Cre (iKO) mice were treated with either 2 mg tamoxifen or vehicle daily for 3 days and then infected with LCMV. Day 10 p.i. analyses of CXCR5 and SLAM staining (gated on GP66-77 IA<sup>b</sup> tetramer<sup>+</sup> CD4 T cells) and numbers of GP66-77 IA<sup>b</sup> tetramer<sup>+</sup> CXCR5<sup>high</sup>SLAM<sup>low</sup> (T<sub>FH</sub>) and CXCR5<sup>low</sup>SLAM<sup>high</sup> (Th1) CD4 T cells in the spleens are shown.


Data in (A)–(D) are from a single experiment (n = 4 per genotype) representing two independent experiments. Data in (E) are from a single experiment (n = 4 per genotype) representative of three independent experiments. Significance was determined by unpaired t tests; error bars represent SD.

SMARTA cells (Figure S4C). We then monitored the differentiation of SMARTA cells at the peak of the immune response (day 8 p.i.) and observed an even more profound loss of T<sub>FH</sub> cells in cKO SMARTA cells compared to that on day 3 p.i. The frequencies of CXCR5<sup>high</sup>SLAM<sup>low</sup> cells (Figure 4D) and CXCR5<sup>high</sup>Bcl6<sup>high</sup> cells (Figures 4E and S4E) were 4- to 5-fold lower in cKO cells than those in their WT counterparts. Similarly, there was close to a 10-fold reduction in the numbers of cKO T<sub>FH</sub> SMARTA cells compared to those of WT, yet no significant difference between the numbers of cKO and WT Th1 cells (Figure S4F).

To delete TCF1 only in naive SMARTA cells, we generated *Tcf7* iKO SMARTA mice and transferred mixed naive SMARTA CD4 T cells from iKO SMARTA mice and their ERT2-Cre<sup>-</sup> counterparts (WT SMARTA) to WT recipients, which then were treated with tamoxifen followed by LCMV infection. Similar to cKO

SMARTA cells, induced deletion of TCF1 preferentially affected T<sub>FH</sub> responses. Both the frequencies and numbers of T<sub>FH</sub> (CXCR5<sup>high</sup>Tim3<sup>low</sup> or CXCR5<sup>high</sup>Bcl6<sup>high</sup>) iKO SMARTA cells on day 3 p.i. were lower than their WT counterparts (Figures S4H–S4J). Again, on day 8 p.i., we observed greater reductions in the frequencies and numbers of T<sub>FH</sub> (CXCR5<sup>high</sup>SLAM<sup>low</sup> or CXCR5<sup>high</sup>Bcl6<sup>high</sup>) cells (Figures 4F, 4G, and S4L) within the iKO SMARTA population, yet Th1 cell numbers were more similar to WT (Figure S4M). Together, our results demonstrate a cell-intrinsic requirement for TCF1 for viral-specific T<sub>FH</sub> cell responses.

Finally, to further evaluate the capacity of *Tcf7*-deficient CD4 T cells to support humoral responses, we adoptively transferred equal numbers of WT or iKO SMARTA CD4 T cells separately into SAP KO mice, which cannot generate GC responses because of defects in CD4 help (Crotty et al., 2003; Qi et al., 2008), treated the chimeras with tamoxifen, and then infected them with LCMV. On day 11 p.i., B cell responses were determined by the numbers of GC (GL7<sup>high</sup>FAS<sup>high</sup>) and activated (Igd<sup>low</sup>FAS<sup>high</sup>) B cells. In SAP KO mice that received iKO SMARTA cells, the numbers of both GC and activated B cells were lower than in those that received WT cells (Figure 4H). Thus, T-cell-intrinsic defects caused by the loss of TCF1 led to a compromised humoral response.



**Figure 4. Loss of TCF1 Causes a Cell-Intrinsic Defect in  $T_{FH}$  Cell Differentiation Early after Infection**

(A–E) As shown in the schematic (A), purified CD4 T cells from cKO (CD45.1<sup>-</sup>CD45.2<sup>+</sup>) and WT (CD45.1<sup>+</sup>CD45.2<sup>-</sup>) SMARTA mice were mixed at ~1:1 ratio and transferred into WT CD45.1 mice (10<sup>6</sup> cells per recipient for day 3 and 10<sup>4</sup> cells for day 8 experiments). Chimeras were then infected with LCMV. TCF1 deletion was confirmed by flow cytometry (Figures S4A and S4D). Data are from a single experiment (n = 4) representative of three independent experiments. Each line represents data from one mouse. (B and C) Frequencies of  $T_{FH}$  (CXCR5<sup>high</sup>Tim3<sup>low</sup> or CXCR5<sup>high</sup>Bcl6<sup>high</sup>) and Th1 (CXCR5<sup>low</sup>Tim3<sup>high</sup>) cells in WT and cKO SMARTA cells in spleens on day 3 p.i. are shown. (D and E) Frequencies of  $T_{FH}$  (CXCR5<sup>high</sup>SLAMF6<sup>low</sup> or CXCR5<sup>high</sup>Bcl6<sup>high</sup>) and Th1 (CXCR5<sup>low</sup>SLAMF6<sup>high</sup>) cells in splenic WT and cKO SMARTA cells on day 8 p.i. are shown.

(F and G) Purified CD4 T cells from iKO (CD45.1<sup>-</sup>CD45.2<sup>+</sup>) and WT (CD45.1<sup>+</sup>CD45.2<sup>-</sup>) SMARTA mice were mixed at ~1:1 ratio and transferred into WT CD45.1 mice, which were then treated with 2 mg tamoxifen for 3 days. Chimeras were infected with LCMV and analyzed on 8 day p.i. for TCF1 (Figure S4K) and for frequencies of  $T_{FH}$  (CXCR5<sup>high</sup>SLAMF6<sup>low</sup> or CXCR5<sup>high</sup>Bcl6<sup>high</sup>) and Th1 (CXCR5<sup>low</sup>SLAMF6<sup>high</sup>) cells in WT and iKO SMARTA cells. Data are from a single experiment (n = 4) representative of three independent experiments. Each line represents data from one mouse.


(H) SAP KO (CD45.2<sup>-</sup>) mice were transferred with 5,000 purified CD4 T cells from iKO or WT SMARTA (CD45.2<sup>-</sup>) mice, treated with 2 mg tamoxifen daily for 3 days, and infected with LCMV, and splenocytes were stained for GC (GL7<sup>high</sup>FAS<sup>high</sup>) B cells and activated (IgD<sup>low</sup>FAS<sup>high</sup>) B cells on day 11 p.i. Flow plots were gated on CD19<sup>+</sup>B220<sup>+</sup> cells. Data are from a single experiment (n = 4) representative of three independent experiments. Statistical significance was determined by paired (B–G) or unpaired (H) t tests; error bars represent SD.

### ***Tcf7* Deficiency Directly Compromises $T_{FH}$ Cell Expansion**

To determine how *Tcf7* deficiency affects  $T_{FH}$  cells, we examined the proliferative capacity of cKO SMARTA cells, as determined by their incorporation of bromodeoxyuridine (BrdU). Interestingly, loss of TCF1 caused a reduction in BrdU incorporation in  $T_{FH}$ , but not Th1, cKO SMARTA cells on day 5 p.i., at the middle of the clonal expansion phase (Figure S4N). Moreover, cKO  $T_{FH}$  cells showed slightly stronger annexin V staining than their WT counterparts, suggesting that cKO  $T_{FH}$  cells may be more prone to apoptosis (Figure S4O). To directly compare the ability of *Tcf7*-deficient and -sufficient  $T_{FH}$  cells to

expand, we sorted WT and iKO  $T_{FH}$  (CXCR5<sup>high</sup>Tim3<sup>low</sup>) and Th1 (CXCR5<sup>low</sup>Tim3<sup>high</sup>) SMARTA cells on day 3 p.i., mixed equal numbers of WT and iKO  $T_{FH}$  or WT and iKO Th1 SMARTA cells, and transferred the mixed  $T_{FH}$  or Th1 cells into infection-matched recipients. Four days post-transfer (day 7 p.i.), ~80% of the progeny from both WT and iKO donor  $T_{FH}$  cells stayed as  $T_{FH}$  cells (CXCR5<sup>high</sup>SLAMF6<sup>low</sup>), while a slightly higher percentage of progeny from iKO donor Th1 cells stayed as Th1 cells than those from WT donor Th1 cells (Figures S4P and S4Q). However, the numbers of progeny from iKO donor  $T_{FH}$  cells were only half the numbers from WT donor  $T_{FH}$  cells, suggesting that *Tcf7* deficiency indeed compromised





**Figure 5. Loss of TCF1 Changes the Transcriptional and Metabolic Signatures of TFH Cells**

(A) Microarray analyses of day 8 TFH (CXCR5<sup>high</sup>SLAM<sup>low</sup>) and Th1 (CXCR5<sup>low</sup>SLAM<sup>high</sup>) cKO and WT SMARTA cells isolated by cell sorting from co-transfer experiments set up as in Figure 4A. Genes expressed >2-fold ( $p < 0.05$ ) in WT TFH cells than in WT Th1 cells were listed as the TFH gene set and those >2-fold ( $p < 0.05$ ) expressed in WT Th1 cells were listed as the Th1 gene set (Table S1). Enrichment of gene sets in cKO relative to WT TFH cells were determined by GSEA. Positive enrichment scores (ESs) indicate enrichment in cKO TFH cells; negative ESs indicate enrichment in WT TFH cells.

(B) Enrichment of gene sets related to branched-chain amino acid degradation, fatty acid metabolism, and citrate cycle in cKO TFH relative to WT TFH cells determined by GSEA using KEGG-curated pathway database is shown.

(C–F) Experiments were set up as in Figure 4A. (C) Comparison of mitochondrial mass between day 8 WT TFH (CXCR5<sup>high</sup>SLAM<sup>low</sup>, solid line) and WT Th1 (CXCR5<sup>low</sup>SLAM<sup>high</sup>, shaded) SMARTA cells, as determined by MitoTracker Green FM, is shown. (D) Mitochondrial mass of day 8 TFH and Th1 cKO (red) and WT (blue) SMARTA cells is shown. (E) Mitochondrial membrane potential of day 8 WT TFH (solid line) and WT Th1 (shaded) SMARTA cells, as determined by the MFI of DiOC6(3) staining, is shown. (F) Mitochondrial membrane potential of day 8 TFH and Th1 cKO (red) and WT (blue) SMARTA cells is shown. Data in (C)–(F) are from single experiments ( $n = 5$ ) representative of two independent experiments. Statistical significance in (C)–(F) was determined by paired t tests. Each line represents data from a single mouse.


the expansion of the transferred TFH cells, likely as a result of reduced proliferation and/or survival.

### Transcriptomic Analyses of Tcf7-Deficient TFH and Th1 Cells

To gain further insights into the properties of Tcf7-deficient TFH and Th1 cells as well as the molecular pathways regulated by TCF1 in these cells, we set up adoptive transfers and infections as described in Figure 4A, and we performed microarray experiments to profile the transcriptomes of WT and cKO TFH and Th1 SMARTA cells sorted from the same mice on day 8 p.i. As the proportion of TFH cells was much lower among cKO SMARTA cells than their WT counterparts, we compared the transcriptomes between WT and cKO cells within the TFH or Th1 subset in order to filter out genes that were differentially expressed simply due to the reduced TFH:Th1 ratio caused by Tcf7 deficiency. We first generated TFH and Th1 signature gene sets by listing genes that were  $\geq 2$ -fold ( $p < 0.05$ ) more expressed in day 8 p.i. WT TFH cells than day 8 p.i. WT Th1 cells or vice versa (Table S1). Then, we used gene set enrichment analysis (GSEA) (Subramanian et al., 2005) to determine whether these signatures were enriched in

cKO cells or WT cells. Strikingly, day 8 p.i. cKO SMARTA TFH cells exhibited reduced TFH gene expression signatures and increased Th1 signatures compared to WT SMARTA TFH cells (Figure 5A).

To better understand pathways affected by Tcf7 deficiency, we performed GSEA to compare the gene signatures of cKO and WT TFH cells using the Kyoto Encyclopedia of Genes and Genomes (KEGG) and reactome-curated pathway databases. cKO TFH cells showed significantly reduced signatures related to gene expression (e.g., basal transcription factors, spliceosome, and aminoacyl-tRNA biosynthesis), DNA repair (e.g., nucleotide excision repair), and cell cycle and metabolism (e.g., valine, leucine, and isoleucine degradation; pentose phosphate pathway; fatty acid metabolism; and citrate cycle) (Tables S2 and S3). The reduced signatures related to branched-chain amino acid degradation, fatty acid degradation, and the citrate cycle in cKO TFH cells (Figure 5B) prompted us to investigate whether Tcf7 deficiency affected mitochondria in TFH cells. Using MitoTracker Green FM to quantify the mitochondrial mass in SMARTA cells, we found that WT TFH cells had higher mitochondrial mass than WT Th1 cells (Figure 5C), suggesting there were metabolic differences between Th1 and TFH cells. Notably,



**Figure 6. TCF1 Suppresses the Expression of *Prdm1* and *Il2ra***

(A and B) qRT-PCR analyses of mRNA levels of *Prdm1* and *Il2ra* in sorted day 3 (A) or day 8 (B) T<sub>FH</sub> and Th1 iKO and WT SMARTA cells, normalized to the mRNA levels of *Actb*. Data are from a single experiment representative of two independent experiments, set up as in Figures 4F and S4G. Statistical significance was determined by an unpaired t test; error bars represent SD.

(C) 10<sup>4</sup> purified CD4 T cells from cKO (CD45.1<sup>-</sup>CD45.2<sup>+</sup>) and WT (CD45.1<sup>+</sup>CD45.2<sup>+</sup>) SMARTA mice were mixed at ~1:1 ratio and adoptively transferred into each of the recipients, which were then infected with LCMV. On day 5 p.i., splenocytes were collected and cultured with or without 50 U/ml human rIL-2 for 20 min at 37°C, and MFI of pSTAT5 in T<sub>FH</sub> cKO and WT SMARTA was determined. Data are from a single experiment (n = 5) representative of two independent experiments. Significance was determined by a paired t test.

(D) ChIP from day 8 T<sub>FH</sub> and Th1 SMARTA cells using antibodies to TCF1 or control IgG and amplified by qRT-PCR for the indicated regions (the third intron of *Prdm1*, the first intron of *Il2ra*, and -23 kb from *Il2ra* TSS). Data are the mean ± SEM of three independent experiments. Significance was determined by an unpaired t test.


we also observed that mitochondrial mass was reduced in cKO SMARTA T<sub>FH</sub> cells and to a lesser extent in cKO SMARTA Th1 cells (Figure 5D). The intensity of DiOC6(3) staining in cells can be used to measure mitochondrial membrane potential, an indicator of mitochondrial function (Rottenberg and Wu, 1998). Again, we found that WT T<sub>FH</sub> cells showed stronger DiOC6(3) staining than WT Th1 cells (Figure 5E). However, both T<sub>FH</sub> and Th1 cKO SMARTA cells showed less DiOC6(3) staining than their WT counterparts (Figure 5F). Together, our data suggest that T<sub>FH</sub> cells exhibit metabolic differences from Th1 cells and, furthermore, that *Tcf7*-deficient T<sub>FH</sub> cells lose these characteristic properties of T<sub>FH</sub> cells. Thus, TCF1 appears to be required to generate and/or maintain T<sub>FH</sub> identity during viral infection.

### TCF1 Negatively Regulates the Expression of CD25 and Blimp1

Among the genes upregulated in cKO T<sub>FH</sub> cells (Table S4) were *Prdm1* and *Il2ra*, which encode Blimp1 and CD25, two proteins

involved in pathways that suppress T<sub>FH</sub> cell differentiation. qRT-PCR results confirmed that *Prdm1* and *Il2ra* transcripts in *Tcf7*-deficient T<sub>FH</sub> cells were higher than those in WT T<sub>FH</sub> cells on day 3 as well as day 8 p.i. (Figures 6A and 6B). The elevated *Il2ra* transcript and surface CD25 levels (Figure S5A) in *Tcf7*-deficient T<sub>FH</sub> cells suggested a potential increase in IL-2 responsiveness. To address this, we cultured WT and cKO SMARTA cells isolated on day 5 p.i. with or without IL-2 and measured IL-2 signaling by staining phosphorylated STAT5 (pSTAT5). The pSTAT5 levels were higher in T<sub>FH</sub> cKO SMARTA cells than in their WT counterparts (Figure 6C), indicating elevated IL-2 signaling in T<sub>FH</sub> cKO cells.

Published TCF1 ChIP-seq data from both thymocytes (Germar et al., 2011) and mature CD8 T cells (Steinke et al., 2014) indicate the presence of TCF1-binding peaks in the third intron of *Prdm1* as well as the first intron of *Il2ra* and a region 23 kb upstream of *Il2ra* TSS (Figures S5B–S5D); the region in the third intron of *Prdm1* has been shown to be important for *Prdm1* expression in other cell types (Tunyaplin et al., 2004). To test whether TCF1 physically interacts with these regions in viral-specific CD4 T cells, we performed TCF1 ChIP experiments on sorted T<sub>FH</sub> and Th1 SMARTA cells. Strikingly, TCF1 bound strongly to all three regions in T<sub>FH</sub> cells, but not in Th1 cells (Figure 6D). Moreover, these TCF1-binding sites showed extensive H3K27me3 modification, associated with transcriptional



**Figure 7. *Tcf7* Deficiency Is Rescued by *Bcl6* Overexpression**

(A) cKO and WT SMARTA CD4 T cells were mixed at ~1:1 ratio, transduced with retroviral constructs overexpressing *Bcl6*, and transferred into WT CD45.1 recipients ( $2 \times 10^4$  cells per recipient) that were then infected with LCMV.

(B) Frequencies of  $T_{FH}$  within WT or cKO SMARTA cells untransduced or transduced with *Bcl6* overexpression construct on day 8 p.i. Data are from a single experiment representative of two independent experiments. Significance was determined by paired t tests.

repression (Cao et al., 2002), in  $T_{FH}$  cells, but not in Th1 cells (Figure S5E). Thus, TCF1 can bind *Prdm1* and *Ii2ra* in  $T_{FH}$  cells, and loss of TCF1 leads to abnormal upregulation of these genes in  $T_{FH}$  cells.

### Rescue of *Tcf7*-Deficient Phenotype by Enforced Expression of *Bcl6*

Our results show that TCF1 in  $T_{FH}$  cells suppressed the expression of *Prdm1* (Figure 6). Given that Blimp1, encoded by *Prdm1*, can be antagonized by *Bcl6* (Crotty, 2011), we reasoned that overexpression of *Bcl6* might rescue the defective  $T_{FH}$  cell differentiation caused by loss of TCF1. To test this hypothesis, we overexpressed *Bcl6* in WT or cKO SMARTA cells through retroviral transduction (Figure 7A). On day 8 p.i., enforced expression of *Bcl6* rectified the defective  $T_{FH}$  cell differentiation in cKO SMARTA cells, greatly increasing the  $T_{FH}$  frequency of cKO SMARTA cells (Figure 7B). Thus, TCF1 acts upstream of the *Bcl6*-Blimp1 axis to regulate  $T_{FH}$  cell responses.

### DISCUSSION

Upon viral or intracellular bacterial infections, effector CD4 T cells differentiate into Th1 cells, which protect the host through secreted cytokines such as  $IFN\gamma$  and  $TNF\alpha$  and/or direct lysis of infected cells, and  $T_{FH}$  cells, which provide help for B cell responses (Choi et al., 2011; Crotty, 2011; Pepper et al., 2011; Swain et al., 2012). The differentiation of  $T_{FH}$  and Th1 cells occurs before GC initiation and depends on DC priming and ICOS-ICOSL interactions between activated CD4 T cells and DCs (Choi et al., 2011; Pepper et al., 2011). However, the molecular mechanisms that govern and maintain the balance of these two distinct subsets are still unclear. TCF1 is critical for thymic T cell development as well as Th2 polarization and the develop-

ment of memory CD8 T cells during immune responses (Weber et al., 2011; Yu et al., 2009b; Zhou et al., 2010). Here we show that viral-specific  $T_{FH}$  cells maintain high levels of TCF1, while viral-specific Th1 cells downregulate TCF1 early after infection. We further demonstrate that both IL-2 and Blimp1 lead to TCF1 downregulation. Importantly, TCF1 was intrinsically required for robust antiviral  $T_{FH}$

cell responses as well as T cell help to B cells; in the absence of TCF1, we observed decreased numbers of  $T_{FH}$  cells and GC B cells, and the remaining *Tcf7*-deficient  $T_{FH}$  cells exhibited reduced  $T_{FH}$  cell transcriptional and metabolic signatures. We provide evidence that TCF1 also acts upstream of the Blimp1-*Bcl6* axis and suppresses expression of both *Prdm1* and *Ii2ra*, the products of which suppress  $T_{FH}$  differentiation.

Previous studies have shown that induction of *Bcl6* and CXCR5 is associated with early  $T_{FH}$  cells, while upregulation of Blimp1 and CD25 is associated with early Th1 cells (Baumjohann et al., 2011; Choi et al., 2011; Pepper et al., 2011). However, the precise timing and details of the mechanisms involved in the commitment of the two lineages remain obscure. In this study, we demonstrate that the pre-GC phase of effector CD4 T cell differentiation can be further divided into two stages. In the first stage, viral-specific CD4 T cells differentiate into either  $TCF1^{high}Blimp1^{low}$   $T_{FH}$  or  $TCF1^{low}Blimp1^{high}$  Th1 cells. The two subsets expressed similar levels of CXCR5 and both could be found in B cell follicles at this stage. In the second stage, Th1 cells lost CXCR5 expression and were now excluded from B cell follicles. Interestingly, early  $T_{FH}$  cells downregulated CD25 rapidly and expressed high levels of *Tcf7*, closely resembling early memory precursor CD8 T cells (Arsenio et al., 2014; Kalia et al., 2010). These cells also have a transcriptional signature similar to memory precursors (Choi et al., 2013). Of note, a subset of CXCR5<sup>+</sup> memory CD4 T cells have been found in the circulation of both human and mice, reiterating a potential shared regulatory network between early viral-specific  $T_{FH}$  cells and early memory precursors (He et al., 2013; Locci et al., 2013). It is interesting to speculate that TCF1 may be a component in this shared signaling network, given its critical role in the development of memory CD8 T cells (Zhou et al., 2010).

Indeed, loss of TCF1 caused a profound defect in the T<sub>FH</sub> cell response to viral infection, as shown here and by two other recent studies (Choi et al., 2015; Xu et al., 2015). It is worth noting, however, that, in our hands, the loss of T<sub>FH</sub> cells in *Tcf7*-deficient SMARTA cells on day 3 p.i. was less dramatic than that on day 8 p.i. It is possible that, while TCF1 is required for optimal T<sub>FH</sub> cell responses prior to GC formation, a redundant mechanism, such as the expression of the related transcription factor LEF1, may compensate for *Tcf7* deficiency during T<sub>FH</sub> differentiation (Choi et al., 2015). However, we also found clear evidence for both reduced proliferation and reduced cell survival of TCF1-deficient T<sub>FH</sub> cells between day 3 and day 7 p.i., which is a major part of the clonal expansion phase. Thus, TCF1 may be required for the full expansion of T<sub>FH</sub> cells, which may account for the differences in the extent of T<sub>FH</sub> defects between day 3 and day 8 p.i. It also should be noted that, although we have not found evidence of conversion from *Tcf7*-deficient T<sub>FH</sub> cells to Th1 cells after tracking them for several days in infection-matched mice, we did see a reduction in T<sub>FH</sub> gene expression and metabolic signatures in the absence of TCF1. TCF1 also can suppress expression of the Th1 cytokine IFN $\gamma$ . Thus, TCF1 may be critical both for T<sub>FH</sub> expansion/survival and for the generation and maintenance of T<sub>FH</sub> identity in the face of strong Th1-inducing signals, as seen in viral infections. In this respect, it is of interest that we have not seen a requirement for TCF1 for T<sub>FH</sub> responses during protein immunization with alum as an adjuvant, which is considered a Th2-inducing condition (T.W., unpublished data).

Previous studies have suggested that signaling mediated by CD25 and Blimp1, which are abundantly expressed in early Th1 cells, inhibits T<sub>FH</sub> cell differentiation (Choi et al., 2011; Johnston et al., 2012; Pepper et al., 2011). Our ChIP and gene expression profiles of *Tcf7*-deficient T<sub>FH</sub> cells suggest that TCF1 potentially represses expression of *Prdm1* and *Ii2ra*. Indeed, CD25 expression was lost much faster in T<sub>FH</sub> cells than in Th1 cells early after infection. Given the high levels of TCF1 in T<sub>FH</sub> cells, TCF1 may contribute to their rapid loss of CD25. Furthermore, since IL-2 signaling increases CD25 expression, this could amplify IL-2 signaling in Th1 cells, generating a positive feedback loop that may contribute to the difference in CD25 expression between the two subsets. It is of note that two recent papers have found that loss of TCF1 or both TCF1 and LEF1 led to reduced Bcl6 as well as increased Blimp1 expression in T<sub>FH</sub> cells (Choi et al., 2015; Xu et al., 2015). While we did not observe decreased Bcl6 expression, we did find that overexpression of Bcl6 rescues T<sub>FH</sub> cell generation in the absence of TCF1, confirming that TCF1 acts upstream of the Blimp1/Bcl6 axes. Moreover, we found that TCF1 not only represses Blimp1 and CD25 expression, but also is repressed by Blimp1 and IL-2, suggesting that TCF1 is a critical component of negative feedback loops with IL-2 and Blimp1 that may regulate the differentiation and maintenance of T<sub>FH</sub> cells during viral infections.

Upon antigen encounter, T cells switch from oxidative phosphorylation to aerobic glycolysis, a pattern that is enforced in Th1 cells by IL-2 (MacIver et al., 2013; Oestreich et al., 2014). However, the metabolic profile of T<sub>FH</sub> cells remains largely unknown. We found that T<sub>FH</sub> cells have greater mitochondrial mass than Th1 cells. An enhanced mitochondrial mass also

was observed in memory T cells, which is correlated with elevated fatty acid oxidation (van der Windt et al., 2012). Interestingly, our gene expression profiling data showed that *Tcf7*-deficient T<sub>FH</sub> cells had reduced gene expression signatures related to branched amino acid degradation, fatty acid degradation, and the citrate cycle, suggesting reduced oxidative metabolism. Consistent with these findings, the loss of TCF1 led to reduced mitochondrial mass and function in T<sub>FH</sub> cells. Thus, TCF1 may contribute to the regulation of T<sub>FH</sub> cell metabolism and promote a more oxidative metabolic profile, although additional studies will be necessary to determine potential targets of TCF1 that contribute to these processes and whether they influence T<sub>FH</sub> cell differentiation.

In summary, our study has demonstrated that the distinct high levels of TCF1 expression distinguish T<sub>FH</sub> cells from Th1 cells and are critical for the development of viral-specific T<sub>FH</sub> cells. In addition, we have identified potential negative feedback loops linking TCF1 to IL-2 and Blimp1. Our findings unveil an essential role of TCF1 in contributing to the balance between immune responses mediated by two major CD4 subsets during viral infection and may help shed light on pathways important for the development of vaccines and immune therapies targeting viral infections.

## EXPERIMENTAL PROCEDURES

### Mice and Infections

*Tcf7* conditional mice (*Tcf7*<sup>tm1a(EUCOMM)Wtsi</sup>, Institut Clinique de la Souris) were crossed to Flip Deleter (7089, Taconic) and either CD4-Cre (Lee et al., 2001) or ERT2-Cre (Seibler et al., 2003) (Taconic) to generate *Tcf7*<sup>loxP/loxP</sup>; CD4-Cre (cKO) or *Tcf7*<sup>loxP/loxP</sup>; ERT2-Cre (iKO) mice, and to SMARTA transgenic mice, expressing a TCR recognizing the LCMV GP66-77 epitope (Oxenius et al., 1998). Blimp1-YFP mice (Fooksman et al., 2014) were crossed to SMARTA mice. Other mouse strains, in vitro activation, retroviral transduction, flow cytometry, microscopy, RNA and protein analyses, ChIP, and luciferase assays are described in the Supplemental Experimental Procedures.

For adoptive transfers, 10<sup>6</sup> (for days 1.5, 2, and 3) or 10<sup>4</sup> (for other time points) SMARTA CD4 T cells were transferred to recipient mice, unless indicated. Mice were intravenously (i.v.) injected with 2 × 10<sup>6</sup> (for days 1.5, 2, and 3) or 2 × 10<sup>5</sup> (for other time points) plaque-forming units (PFUs) of LCMV Armstrong. For ERT2-Cre inducible KOs, 2 mg tamoxifen in corn oil was injected intraperitoneally (i.p.) daily for 3–5 days before LCMV infection. Controls were either Cre<sup>-</sup> mice or mice transferred with ERT2-Cre<sup>-</sup> SMARTA injected with tamoxifen or ERT2-Cre<sup>+</sup> animals injected with vehicle. All animal husbandry and experiments were approved by the NHGRI or NINDS Animal Use and Care Committees.

### Statistical Analysis

Two-tailed paired or unpaired Student's t test was performed with GraphPad Prism 6 to calculate p values (\*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001, and \*\*\*\*p < 0.0001).

### ACCESSION NUMBERS

The accession number for the microarray data reported in this paper is GEO: GSE65660.

### SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, five figures, and four tables and can be found with this article online at <http://dx.doi.org/10.1016/j.celrep.2015.08.049>.



## ACKNOWLEDGMENTS

We thank J. Reilley, R. Handon, M. Kirby, S. Anderson, J. Fekecs, and E. Stregevsky for excellent technical support. This work was supported by funds from the intramural programs of the NHGRI, NINDS, NCI, and NIA, as well as NIH grant AI101048 (L.J.B.).

Received: February 22, 2015

Revised: August 3, 2015

Accepted: August 18, 2015

Published: September 10, 2015

## REFERENCES

- Allen, C.D., Okada, T., and Cyster, J.G. (2007). Germinal-center organization and cellular dynamics. *Immunity* 27, 190–202.
- Arsenio, J., Kakaradov, B., Metz, P.J., Kim, S.H., Yeo, G.W., and Chang, J.T. (2014). Early specification of CD8<sup>+</sup> T lymphocyte fates during adaptive immunity revealed by single-cell gene-expression analyses. *Nat. Immunol.* 15, 365–372.
- Ballesteros-Tato, A., León, B., Graf, B.A., Moquin, A., Adams, P.S., Lund, F.E., and Randall, T.D. (2012). Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. *Immunity* 36, 847–856.
- Baumjohann, D., Okada, T., and Ansel, K.M. (2011). Cutting Edge: Distinct waves of BCL6 expression during T follicular helper cell development. *J. Immunol.* 187, 2089–2092.
- Cannons, J.L., Lu, K.T., and Schwartzberg, P.L. (2013). T follicular helper cell diversity and plasticity. *Trends Immunol.* 34, 200–207.
- Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R.S., and Zhang, Y. (2002). Role of histone H3 lysine 27 methylation in Polycomb-group silencing. *Science* 298, 1039–1043.
- Choi, Y.S., Kageyama, R., Eto, D., Escobar, T.C., Johnston, R.J., Monticelli, L., Lao, C., and Crotty, S. (2011). ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6. *Immunity* 34, 932–946.
- Choi, Y.S., Yang, J.A., Yusuf, I., Johnston, R.J., Greenbaum, J., Peters, B., and Crotty, S. (2013). Bcl6 expressing follicular helper CD4 T cells are fate committed early and have the capacity to form memory. *J. Immunol.* 190, 4014–4026.
- Choi, Y.S., Gullicksrud, J.A., Xing, S., Zeng, Z., Shan, Q., Li, F., Love, P.E., Peng, W., Xue, H.H., and Crotty, S. (2015). LEF-1 and TCF-1 orchestrate TFH differentiation by regulating differentiation circuits upstream of the transcriptional repressor Bcl6. *Nat. Immunol.*
- Crotty, S. (2011). Follicular helper CD4 T cells (TFH). *Annu. Rev. Immunol.* 29, 621–663.
- Crotty, S., Kersh, E.N., Cannons, J., Schwartzberg, P.L., and Ahmed, R. (2003). SAP is required for generating long-term humoral immunity. *Nature* 421, 282–287.
- Fooksman, D.R., Nussenzweig, M.C., and Dustin, M.L. (2014). Myeloid cells limit production of antibody-secreting cells after immunization in the lymph node. *J. Immunol.* 192, 1004–1012.
- Germar, K., Dose, M., Konstantinou, T., Zhang, J., Wang, H., Lobry, C., Arnett, K.L., Blacklow, S.C., Aifantis, I., Aster, J.C., and Gounari, F. (2011). T-cell factor 1 is a gatekeeper for T-cell specification in response to Notch signaling. *Proc. Natl. Acad. Sci. USA* 108, 20060–20065.
- Haynes, N.M., Allen, C.D., Lesley, R., Ansel, K.M., Killeen, N., and Cyster, J.G. (2007). Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1 high germinal center-associated subpopulation. *J. Immunol.* 179, 5099–5108.
- He, J., Tsai, L.M., Leong, Y.A., Hu, X., Ma, C.S., Chevalier, N., Sun, X., Vandenberg, K., Rockman, S., Ding, Y., et al. (2013). Circulating precursor CCR7(10) PD-1(hi) CXCR5<sup>+</sup> CD4<sup>+</sup> T cells indicate Tfh cell activity and promote antibody responses upon antigen reexposure. *Immunity* 39, 770–781.
- Jenuwein, T., and Allis, C.D. (2001). Translating the histone code. *Science* 293, 1074–1080.
- Jin, H.T., Anderson, A.C., Tan, W.G., West, E.E., Ha, S.J., Araki, K., Freeman, G.J., Kuchroo, V.K., and Ahmed, R. (2010). Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. *Proc. Natl. Acad. Sci. USA* 107, 14733–14738.
- Johnston, R.J., Poholek, A.C., DiToro, D., Yusuf, I., Eto, D., Barnett, B., Dent, A.L., Craft, J., and Crotty, S. (2009). Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. *Science* 325, 1006–1010.
- Johnston, R.J., Choi, Y.S., Diamond, J.A., Yang, J.A., and Crotty, S. (2012). STAT5 is a potent negative regulator of TFH cell differentiation. *J. Exp. Med.* 209, 243–250.
- Kalia, V., Sarkar, S., Subramaniam, S., Haining, W.N., Smith, K.A., and Ahmed, R. (2010). Prolonged interleukin-2R $\alpha$  expression on virus-specific CD8<sup>+</sup> T cells favors terminal-effector differentiation in vivo. *Immunity* 32, 91–103.
- Kuo, T.C., and Calame, K.L. (2004). B lymphocyte-induced maturation protein (Blimp)-1, IFN regulatory factor (IRF)-1, and IRF-2 can bind to the same regulatory sites. *J. Immunol.* 173, 5556–5563.
- Lee, P.P., Fitzpatrick, D.R., Beard, C., Jessup, H.K., Lehar, S., Makar, K.W., Pérez-Melgosa, M., Sweetser, M.T., Schlissel, M.S., Nguyen, S., et al. (2001). A critical role for Dnmt1 and DNA methylation in T cell development, function, and survival. *Immunity* 15, 763–774.
- Locci, M., Havenar-Daughton, C., Landais, E., Wu, J., Kroenke, M.A., Arlehamn, C.L., Su, L.F., Cubas, R., Davis, M.M., Sette, A., et al.; International AIDS Vaccine Initiative Protocol C Principal Investigators (2013). Human circulating PD-1+CXCR3-CXCR5+ memory Tfh cells are highly functional and correlate with broadly neutralizing HIV antibody responses. *Immunity* 39, 758–769.
- MacIver, N.J., Michalek, R.D., and Rathmell, J.C. (2013). Metabolic regulation of T lymphocytes. *Annu. Rev. Immunol.* 31, 259–283.
- Nurieva, R.I., Chung, Y., Martinez, G.J., Yang, X.O., Tanaka, S., Matskevitch, T.D., Wang, Y.H., and Dong, C. (2009). Bcl6 mediates the development of T follicular helper cells. *Science* 325, 1001–1005.
- Oestreich, K.J., Mohn, S.E., and Weinmann, A.S. (2012). Molecular mechanisms that control the expression and activity of Bcl-6 in TH1 cells to regulate flexibility with a TFH-like gene profile. *Nat. Immunol.* 13, 405–411.
- Oestreich, K.J., Read, K.A., Gilbertson, S.E., Hough, K.P., McDonald, P.W., Krishnamoorthy, V., and Weinmann, A.S. (2014). Bcl-6 directly represses the gene program of the glycolysis pathway. *Nat. Immunol.* 15, 957–964.
- Okamura, R.M., Sigvardsson, M., Galceran, J., Verbeek, S., Clevers, H., and Grosschedl, R. (1998). Redundant regulation of T cell differentiation and TCR $\alpha$  gene expression by the transcription factors LEF-1 and TCF-1. *Immunity* 8, 11–20.
- Oxenius, A., Bachmann, M.F., Zinkernagel, R.M., and Hengartner, H. (1998). Virus-specific MHC-class II-restricted TCR-transgenic mice: effects on humoral and cellular immune responses after viral infection. *Eur. J. Immunol.* 28, 390–400.
- Pepper, M., Pagán, A.J., Igyártó, B.Z., Taylor, J.J., and Jenkins, M.K. (2011). Opposing signals from the Bcl6 transcription factor and the interleukin-2 receptor generate T helper 1 central and effector memory cells. *Immunity* 35, 583–595.
- Qi, H., Cannons, J.L., Klauschen, F., Schwartzberg, P.L., and Germain, R.N. (2008). SAP-controlled T-B cell interactions underlie germinal centre formation. *Nature* 455, 764–769.
- Rottenberg, H., and Wu, S. (1998). Quantitative assay by flow cytometry of the mitochondrial membrane potential in intact cells. *Biochim. Biophys. Acta* 1404, 393–404.
- Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., and Anderson, A.C. (2010). Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. *J. Exp. Med.* 207, 2187–2194.

- Seibler, J., Zevnik, B., Küter-Luks, B., Andreas, S., Kern, H., Hennek, T., Rode, A., Heimann, C., Faust, N., Kauselmann, G., et al. (2003). Rapid generation of inducible mouse mutants. *Nucleic Acids Res.* *31*, e12.
- Staal, F.J., and Clevers, H. (2000). Tcf/Lef transcription factors during T-cell development: unique and overlapping functions. *The hematology journal* *1*, 3–6.
- Steinke, F.C., Yu, S., Zhou, X., He, B., Yang, W., Zhou, B., Kawamoto, H., Zhu, J., Tan, K., and Xue, H.H. (2014). TCF-1 and LEF-1 act upstream of Th-POK to promote the CD4(+) T cell fate and interact with Runx3 to silence Cd4 in CD8(+) T cells. *Nat. Immunol.* *15*, 646–656.
- Subramanian, A., Tamayo, P., Mootha, V.K., Mukherjee, S., Ebert, B.L., Gillette, M.A., Paulovich, A., Pomeroy, S.L., Golub, T.R., Lander, E.S., and Mesirov, J.P. (2005). Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc. Natl. Acad. Sci. USA* *102*, 15545–15550.
- Swain, S.L., McKinstry, K.K., and Strutt, T.M. (2012). Expanding roles for CD4<sup>+</sup> T cells in immunity to viruses. *Nat. Rev. Immunol.* *12*, 136–148.
- Tunyaplin, C., Shaffer, A.L., Angelin-Duclos, C.D., Yu, X., Staudt, L.M., and Calame, K.L. (2004). Direct repression of *prdm1* by Bcl-6 inhibits plasmacytic differentiation. *J. Immunol.* *173*, 1158–1165.
- Van de Wetering, M., Castrop, J., Korinek, V., and Clevers, H. (1996). Extensive alternative splicing and dual promoter usage generate Tcf-1 protein isoforms with differential transcription control properties. *Mol. Cell. Biol.* *16*, 745–752.
- van der Windt, G.J., Everts, B., Chang, C.H., Curtis, J.D., Freitas, T.C., Amiel, E., Pearce, E.J., and Pearce, E.L. (2012). Mitochondrial respiratory capacity is a critical regulator of CD8<sup>+</sup> T cell memory development. *Immunity* *36*, 68–78.
- Verbeek, S., Izon, D., Hofhuis, F., Robanus-Maandag, E., te Riele, H., van de Wetering, M., Oosterwegel, M., Wilson, A., MacDonald, H.R., and Clevers, H. (1995). An HMG-box-containing T-cell factor required for thymocyte differentiation. *Nature* *374*, 70–74.
- Victora, G.D., and Nussenzweig, M.C. (2012). Germinal centers. *Annu. Rev. Immunol.* *30*, 429–457.
- Weber, B.N., Chi, A.W., Chavez, A., Yashiro-Ohtani, Y., Yang, Q., Shestova, O., and Bhandoola, A. (2011). A critical role for TCF-1 in T-lineage specification and differentiation. *Nature* *476*, 63–68.
- Xu, L., Cao, Y., Xie, Z., Huang, Q., Bai, Q., Yang, X., He, R., Hao, Y., Wang, H., Zhao, T., et al. (2015). The transcription factor TCF-1 initiates the differentiation of TFH cells during acute viral infection. *Nat. Immunol.*
- Xue, H.H., and Zhao, D.M. (2012). Regulation of mature T cell responses by the Wnt signaling pathway. *Ann. N Y Acad. Sci.* *1247*, 16–33.
- Yu, D., Rao, S., Tsai, L.M., Lee, S.K., He, Y., Sutcliffe, E.L., Srivastava, M., Linterman, M., Zheng, L., Simpson, N., et al. (2009a). The transcriptional repressor Bcl-6 directs T follicular helper cell lineage commitment. *Immunity* *31*, 457–468.
- Yu, Q., Sharma, A., Oh, S.Y., Moon, H.G., Hossain, M.Z., Salay, T.M., Leeds, K.E., Du, H., Wu, B., Waterman, M.L., et al. (2009b). T cell factor 1 initiates the T helper type 2 fate by inducing the transcription factor GATA-3 and repressing interferon-gamma. *Nat. Immunol.* *10*, 992–999.
- Yu, S., Zhou, X., Steinke, F.C., Liu, C., Chen, S.C., Zagorodna, O., Jing, X., Yokota, Y., Meyerholz, D.K., Mullighan, C.G., et al. (2012). The TCF-1 and LEF-1 transcription factors have cooperative and opposing roles in T cell development and malignancy. *Immunity* *37*, 813–826.
- Zhou, L., Chong, M.M., and Littman, D.R. (2009). Plasticity of CD4<sup>+</sup> T cell lineage differentiation. *Immunity* *30*, 646–655.
- Zhou, X., Yu, S., Zhao, D.M., Harty, J.T., Badovinac, V.P., and Xue, H.H. (2010). Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1. *Immunity* *33*, 229–240.